Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer

被引：1

作者：

H. Obata

Y. Aoki

M. Watanabe

H. Matsushita

T. Yahata

K. Fujita

H. Kurata

K. Tanaka

机构：

[1] Department of Obstetrics, Niigata Univ. Grad. Sch. Med./D. S., Niigata 951-8510

来源：

International Journal of Clinical Oncology | 2003年 / 8卷 / 1期

关键词：

Carboplatin; Docetaxel; Recurrent endometrial cancer;

D O I：

10.1007/s101470300008

中图分类号：

学科分类号：

摘要：

There is no consensus regarding the optimal chemotherapy for endometrial cancer patients, and a need for better chemotherapy is evident. Two individuals with recurrent metastatic endometrial cancer treated with docetaxel and carboplatin combination chemotherapy are presented here. Both cases showed objective response to the chemotherapy (one complete response and the other partial response); response duration was 7 and 18 months, respectively. One patient who achieved complete response is alive without disease for 12 months after recurrence. Adverse effects in this regimen were mild and tolerable. Docetaxel in combination with carboplatin may be active agents for patients with metastatic endometrial cancer.

引用

页码：53 / 55

页数：2

共 8 条

[1] Tominaga S., Oshima A., Cancer Mortality and Morbidity Statistics. Gann Monograph on Cancer Research No 47, (1995)
[2] Aoki Y., Kase H., Watanabe M., Et al., Stage III endometrial cancer: Analysis of prognostic factors, and failure patterns after adjuvant chemotherapy, Gynecol Oncol, 83, pp. 1-5, (2001)
[3] Thigpen T., Blessing J., Homesley H., Et al., Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: A Gynecological Oncology Group (GOG) study, Proc Am Soc Clin Oncol, 12, (1993)
[4] Dimopoulos M.A., Papadimitriou C.A., Georgoulias V., Et al., Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study, Gynecol Oncol, 78, pp. 52-57, (2000)
[5] Hoskins P.J., Swenerton K.D., Pike J.A., Et al., Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study, J Clin Oncol, 19, pp. 4048-4053, (2001)
[6] Vasey P.A., Survival and longer-term toxicity results of the SCOTROC study: Docetaxel-carboplatin (DC) vs. paclitaxelcarboplatin (PC) in epithelial ovarian cancer (EOC), Proc Am Soc Clin Oncol, 21, (2002)
[7] Gunthert A.R., Pilz S., Kuhn W., Et al., Docetaxel is effective in the treatment of metastatic endometrial cancer, Anticancer Res, 19, pp. 3459-3461, (1999)
[8] Markman M., Kennedy A., Webster K., Et al., Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum, J Clin Oncol, 19, pp. 1901-1905, (2001)

← 1 →